MannKind Corporation Aktie News

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD's 2026 business outlook highlights expanding commercial assets, key regulatory milestones, and a strong pipeline, positioning 2026 as a potential breakout year. Afrezza's FDA label update removes adoption barriers, expanding its addre...

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin

MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 5 of this series includes Hormel Foods, IonQ, Kodiak AI, Lara Exploration and MannKind.

Top stock-market newsletter editors share gems from their ‘buy' list.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (MNKD +0.00%), executed an exercise and immediate sale of 65,804 common shares for a transaction value of approximately $395,482, according to the SEC Form 4 filing.

FDA approves FUROSCIX ® for use in pediatric patients weighing 43kg or above USPTO issues five patents for FUROSCIX ReadyFlow ™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass.